| Literature DB >> 15922257 |
Martin W Bienengraeber1, Dorothee Weihrauch, Judy R Kersten, Paul S Pagel, David C Warltier.
Abstract
Preconditioning describes a very powerful endogenous mechanism by which the heart may be protected against ischemia and reperfusion injury. Transient administration of a volatile anesthetic before a prolonged ischemic episode reduces myocardial infarct size to a degree comparable to that observed during ischemic preconditioning. Many components of the signal transduction pathways responsible for cardioprotection are shared by anesthetic and ischemic preconditioning. Exposure to volatile anesthetics generates small "triggering" quantities of reactive oxygen species (ROS) by directly interacting with the mitochondrial electron transport chain or indirectly through a signaling cascade in which G-protein-coupled receptors, protein kinases, and mitochondrial ATP-sensitive potassium (K(ATP)) channels play important roles. Several clinical studies also suggest that preconditioning by volatile anesthetics exerts beneficial effects in patients undergoing cardiac surgery. This review summarizes some of the recent major developments in the understanding of cardioprotection by volatile anesthetics.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15922257 DOI: 10.1016/j.vph.2005.02.005
Source DB: PubMed Journal: Vascul Pharmacol ISSN: 1537-1891 Impact factor: 5.773